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Carnitines play an important role in the energy exchange in cells, involved in the transport 
of fatty acids across the inner mitochondrial membrane. L-Acetylcarnitine (ALCAR) is an acetic 
acid ester of carnitine that has higher bioavailability than carnitine and is considered a fat-burning 
energizer supplement. We previously found that in serum samples from prostate cancer (PCa) 
patients, 3 carnitine family members were significantly decreased, suggesting a potential protective 
role of carnitine against PCa. Several studies support beneficial effects of carnitines on cancer, no 
study has investigated the activities of carnitine o  tumor angiogenesis.  
We examined whether ALCAR act as an “angiopreventiv” compound and studied the 
molecular mechanisms involved. We found that ALCAR was able to limit inflammatory 
angiogenesis by reducing stimulated endothelial cell and macrophage infiltration in vitro and in 
vivo. Molecularly, we showed that ALCAR downregulates VEGF, VEGFR2, CXCL12, CXCR4 
and FAK pathways. ALCAR blocked the activation of NF-κB and ICAM-1 and reduced the 
adhesion of a monocyte cell line to endothelial cels. This is the first study showing that ALCAR 
has anti-angiogenesis and anti-inflammatory properties and might be attractive candidate for cancer 
angioprevention. 
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patients, 3 carnitine family members were significantly decreased, suggesting a potential protective 17 
role of carnitine against PCa. Several studies support beneficial effects of carnitines on cancer, no 18 
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List of abbreviations 38 
 39 
ALCAR Acetyl – L – Carnitine  
ANGPT1 Angiopoietin-1 
BPH Benign Prostatic Hyperplasia 
CPT1A Carnitine Palmitoyl Transferase 1 
CPT1C Carnitine O – Palmitoyl Transferase 1 
CXCR4 C-X-C chemokine receptor type 4 
FAO Fatty Acid Oxidation 
FGF2 Fibroblast Growth Factor 2 
Hif-1α Hypoxia- inducible Factor 1-alpha 
HUVECs Human Umbilical Vein Endothelial Cells 
ICAM-1 Intracellular Cell Adhesion Molecule – 1  
CCL2 MCP-1; Monocyte Chemoattractant Protein-1 
NF-ᴋB Nuclear Factor Kappa-Light-Chain-Enhancer of Activa ed B Cells 
p-38 MAPK Cytokinin Specific Binding Protein 
PCa Prostate Cancer 
PECAM-1 Platelet and Endothelial Cell Adhesion Molecul -1 
ERK 1/2 Extracellular signal – Regulated protein Kinases 1 and 2 
PLCγ1 Phospholipase C, gamma 1 
FAK  Focal Adhesion Kinase 
Src Proto-Oncogene Tyrosine – Protein Kinase 
SACI Surface – Activated Chemical Ionization 
SANIST Rapid mass spectrometric SACI/ESI data acquisition and elaboration platform 
CXCL12 SDF-1; Stromal Cell-Derived Factor-1 
THP-1 Leukemic Monocyte 
TNFα Tumor Necrosis Factor α
VCAM-1 Vascular Cell Adhesion Molecule – 1  
VEGF Vascular Endothelial Growth Factor 
VEGFR2 Vascular Endothelial Growth Factor Receptor 2 
 40 
  41 
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1. INTRODUCTION  42 
Angiogenesis is a process characterized by the formation of new blood vessels from pre-43 
existing ones, acting as a crucial vascular orchestrator both in physiological and pathological 44 
conditions [22, 24, 41, 82]. A strict physiological balance between endogenous pro-angiogenic and 45 
anti-angiogenic factors regulate the endothelial cell growth and angiogenesis [29]. Induction of 46 
aberrant angiogenesis represents a shared hallmark in several chronic inflammatory diseases, such 47 
as diabetes, cardiovascular diseases, metabolic syndrome and cancer [22]. Tumor angiogenesis is 48 
essential for oxygen and nutrient delivery to growing tumors and provides a roadway to disseminate 49 
to distant organs [22, 29]. Increased attention has been addressed to approaches aimed at preventing 50 
cancer by suppressing angiogenesis, leading to the concept of angioprevention [6]. Current 51 
clinically employed anti-angiogenic agents target the vascular endothelial growth factor (VEGF) 52 
pathway [47]. However, most of clinically employed anti-angiogenic drugs are only effective in a 53 
subset of patients, usually relapse occurs, and they ar  not without toxicities [80]. Therefore, the 54 
identification of new anti-angiogenic compounds which could overcome these drawbacks are 55 
urgently needed. During the last decades, great efforts have been addressed to diverse diet derived 56 
compounds (nutraceuticals), that have been explored for their ability to prevent or slow down 57 
cancer, given their anti-proliferative, anti-inflammatory, anti-oxidant and pro apoptotic activities [1, 58 
6, 10, 13, 46, 54, 62, 75-77, 81]. Many of these agnts also have been observed to block tumor 59 
progression by inhibiting angiogenesis [6, 25, 26, 74 78]. Major features of these agents are 60 
represented by their low toxicity, and high tolerability over long term administration. 61 
Carnitine (β-hydroxy-γ-N-trimethylaminobutyric acid) is a naturally occurring quaternary 62 
ammonium compound and its derivatives acetyl-L-carnitine and propionyl-L-carnitine, are essential 63 
for lipid energy metabolism within the mitochondria, contributing to the transport of long-chain 64 
acyl CoA into the mitochondrial matrix where the enzymes for β-oxidation are located. Other roles 65 
for carnitine include buffering of branched-chain amino acid metabolism, removal of excess acyl 66 
groups, and peroxisomal fatty acid oxidation [18, 32]. Carnitine deficiency have been observed in 67 
diverse disorders, such as diabetes, sepsis, cardiomyopathy, malnutrition, cirrhosis, endocrine 68 
disorders and those related with aging [32]. Low plasma carnitine levels have been found in cancer 69 
patients, ascribed to malnutrition [64]. Clinically, L-carnitine (LC) and its derivatives (acetyl-LC; 70 
propionyl-LC) are under study to combat wasting andchemotherapy-induced peripheral neuropathy 71 
[21, 68]. 72 
Through metabolomics approaches we had previously found that in serum samples from 73 
PCa patients, 3 molecules from the carnitine family (decanoyl-L-Carnitine, octanoyl-L-carnitine 74 
and 5-cis-tetradecenoyl carnitine) were significantly decreased as compared to those from 75 
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individuals with BPH, suggesting a potential protective role of carnitine against PCa [3]. Carnitine 76 
supplementation in several experimental models has been shown to slow down tumor growth by 77 
inhibiting histone deacetylases (HDAC) [39]. Furthe, inhibition of carnitine palmitoyltransferases 78 
(CPT1A and CPT1C) also results in inhibition of tumor growth [55, 67, 73, 79]. Obese mice 79 
consuming curcumin, a known angiogenesis inhibitor, showed enhanced carnitine CPT1 activity 80 
[28], and carnitines showed synergism with curcumin in a colon cancer model [56].  81 
Considering the key role of fatty acid oxidation (FAO) as an important regulator of 82 
angiogenesis [69, 79], we investigated whether carnitines may exert anti-angiogenic and 83 
angioprevention properties in vitro and in vivo and the potential molecular pathways involved. We 84 
focused our experiments on the acetylated form of L-carnitine, acetyl-L-carnitine (ALCAR) given 85 
that it has higher bioavailability than L-carnitine [66]. ALCAR is a component of several 86 
supplement formulations and largely available in the nutraceutical market. 87 
Angiogenesis and inflammation are two host-derived hallmarks of cancer that are linked 88 
together [36]. Here, we investigated for the first time whether ALCAR targets inflammatory 89 
angiogenesis by limiting key functional activities on cytokine-activated human umbilical vein 90 
endothelial cells (HUVEC) in normoxic, hypoxic and inflammatory environments. ALCAR 91 
significantly inhibited angiogenesis, and it downregulates VEGF and VEGFR2 and key down-92 
stream protein kinases, including pTyr397-FAK, pTyr416-Src, p-38 MAPK, and p-Ser1248-PLCγ1. 93 
Within the  tumor microenvironment the interaction f CXCL12 with its receptors represents a 94 
potential target in tumor angiogenesis [42]. We found that ALCAR affected migration and invasion 95 
of endothelial cells and inhibits the CXCL12/CXCR4 axis. We also found that ALCAR reduced the 96 
TNFα-induced adhesion of macrophages (THP-1) to an endothelial cell monolayer and inhibited 97 
inflammatory angiogenesis by inhibiting NF-κB activation and reduced the expression of ICAM-1. 98 
These results were consistent with in vivo data in the matrigel sponge assay, where we show an 99 
inhibition of angiogenesis and inflammation by substantially and significantly lowers endothelial 100 
cell and macrophage recruitment into the matrigel plugs. Our results identified cellular and 101 
molecular mechanisms related with ALCAR anti-angiogenic and angiopreventive properties and 102 
provide the rational for the employment of ALCAR, as supplement for approaches of interception 103 
and prevention of cancer. 104 
 105 
2. 2.1 Chemicals and reagents 106 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), acetyl-L-Carnitine 107 
(ALCAR) were from Sigma Aldrich. 108 
 109 
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2.2 Cell culture 110 
HUVE cells (human umbilical vein endothelial cells) were from Promocell and cultured in 111 
endothelial cell basal medium (EBM™, Lonza) supplemented with endothelial cell growth medium 112 
(EGM™SingleQuots™, Lonza), 10% Fetal Bovine Serum (FBS), 2mM L-glutamine, 100 U/mL 113 
penicillin and 100 µg/mL streptomycin and were used b tween the 3-5 passage. MRC-5 (PD 30) 114 
cell line from Sigma were cultured on EMEM (EBSS) supplemented with 10% FBS, 2mM L-115 
glutamine, 1% non-essential amino acids, 100 U/mL penicillin and 100 µg/mL streptomycin. The 116 
human monocytic cell line (THP-1) from ATCC were cultured in cell suspension in RPMI 1640 117 
supplemented with 10% FBS, 2mM L-glutamine, 0.5mM β-mercaptoethanol, 100 U/mL penicillin 118 
and 100 µg/mL streptomycin. Peripheral blood mononuclear cells (PBMCs) were obtained by 119 
whole blood samples subjected to a density gradient stra ification and maintained at 106 cells/mL 120 
density in RPMI 1640 supplemented with 10% FBS 2mM L-glutamine, 100 UI/mL recombinant 121 
human IL2 (R&D), 100 U/ml penicillin and 100 µg/mL streptomycin. 122 
 123 
2.3 Functional in vitro angiogenesis assays 124 
2.3.1 Tube formation 125 
The effects of ALCAR on endothelial cell ability to f rm capillary-like structures on 126 
basement membrane matrix was assessed in vitro, using the morphogenesis assay. HUVE cells were 127 
grown on EBM2 complete medium and when 80% confluent were serum starved overnight. A 24-128 
well plate, pre-chilled at -20°C, was carefully filled with 300µL of liquid matrigel (BD Biosciences) 129 
per well at 4°C and then polymerized for 1h at 37°C. 5 × 104 of HUVE cells/well were suspended in 130 
1 mL of EBM2 medium containing 100 ng/mL VEGF and 100 ng/mL FGF2 alone or with 1-10 131 
mM ALCAR and layered on the top of the polymerized matrigel. Positive and negative controls 132 
received 10% FBS or serum free EBM2 medium, respectively. The effects on HUVEC tube 133 
formation were captured after 6 h incubation using a Zeiss Microscope associated with a Nikon 134 
camera (Axio Observer A1, Zeiss, Germany) and quantified using ImageJ software and the 135 
“Angiogenesis Analyzer” tool. Experiments were performed on HUVEC cells either at basal level 136 
or activated with TNFα (10 ng/ml) or incubated in a hypoxic chamber (Eppendorf, Germany) at an 137 
atmosphere of 1% O2, 94% N2, 5% CO2 at 37°C for 72 h, while the control cells were incubated in 138 
an atmosphere of 21% O2 and 5% CO2 at 37°C.  139 
 140 
2.3.2 Adhesion 141 
 HUVE cells were pre-treated with 1 or 10 mM ALCAR for 24 h in complete medium. 142 
Control cells received complete medium alone. Following treatment, 3x103 cells were seeded on 4-143 
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well chamber slides, pre-coated with 2 µg/ml fibronectin (Sigma Aldrich), for 45 min at 37°C, 5% 144 
CO2. Following 90 mins of incubation, medium was removed, cells washed with PBS and fixed 145 
with 4% paraformaldehyde (PFA) and stained with DAPI (Sigma Aldrich). Assays were performed 146 
in triplicates.  Cells within five blinded fields for each condition were counted using a Zeiss 147 
microscope. Experiments were performed on HUVEC cells either at basal level or activated with 148 
TNFα (10 ng/ml), as indicated. 149 
 150 
2.3.3 Migration and invasion 151 
A modified Boyden Chamber, as described in [2, 5] was used to perform migration and 152 
invasion assays. HUVE cells were pre-treated with 1 or 0 mM ALCAR for 24 h. 10 µm pore-size 153 
polycarbonate filters, pre-coated with matrigel (1 mg/ l, BD) for chemoinvasion assay and with 154 
collagen IV (50 µg/ml, Sigma Aldrich) for chemotaxis assay [2, 5] were used as the interface 155 
between the two chamber compartments. Following 6h (chemotaxis) or 24h (chemoinvasion) of 156 
incubation at 37°C in 5% CO2, the filters were collected, cells on the upper surface mechanically 157 
removed using a cotton swab and migrated or invaded cells on the lower filter surface were fixed 158 
with absolute ethanol and stained with DAPI. Migrated/invaded cells were counted in a double-159 
blind manner in 5 consecutive fields using a Zeiss Microscope associated with a Nikon camera 160 
(Axio Observer A1, Zeiss, Germany). 161 
  162 
2.4 Real Time PCR 163 
Total RNA was extracted using small RNA miRNeasy Mini Kit (Qiagen) and quantified in a 164 
Nanodrop Spectrophotometer. Reverse transcription was performed using SuperScript VILO cDNA 165 
synthesis kit (Thermo Fisher). Real-time PCR was performed using SYBR Green Master Mix 166 
(Applied Biosystems) on QuantStudio 6 Flex Real-Time PCR System Software (Applied 167 
Biosystems). All reactions were performed in triplicate. The relative gene expression was expressed 168 
relative to non-treated cells normalized to the housekeeping gene. Gene expression analysis was 169 
performed using the primers shown in supplementary Table 1. Experiments were performed on 170 
HUVEC cells either at basal level or activated with TNFα (10 ng/ml), as indicated. 171 
 172 
2.5 Western blotting 173 
Cells were lysed in RIPA buffer containing protease and phosphatase inhibitor cocktails 174 
(Roche Diagnostics GmbH, Mannheim, Germany). Protein concentration was determined by 175 
Bradford assay using bovine serum albumin (BSA; Sigma-Aldrich) as standard. Proteins (25µg) 176 
were separated on the NupageNovex 10% Bis-Tris gel or on 4–12% Bis-Tris Gel (Life 177 
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Technologies) and then transferred to a PVDF membrane (Amersham Hybond). The membrane was 178 
blocked with 5% (v/v) non-fat dry milk in Tween 20 (Sigma-Aldrich) in PBS for 1 hour and then 179 
incubated overnight at 4°C with the following primary antibodies: anti-VEGFR2, anti-HIF-1α, anti-180 
NF-κB p65, anti-p-38 MAPK, anti-p-Src, anti-FAK, anti-p-PLCγ1 (all from Cell Signaling 181 
Technology), anti-VEGF (Santa Cruz), anti-ICAM-1 and anti-VCAM-1 (Abcam). 182 
After a triple wash with 0.1% (v/v) PBS/Tween, membranes were incubated with the 183 
secondary antibody peroxidase-linked anti-rabbit IgG or anti-mouse IgG (GE Healthcare Life 184 
science) diluted at 1:3000 for 1 hour at room temperature. Specific protein bands were detected 185 
with Pierce ECL Western Blotting Substrate (ThermoFisher Scientific). Protein expressions were 186 
normalized to beta-Actin at 1:5000 (Abcam). Western-blot data were analyzed using ImageJ 187 
software to determine optical density (OD) of the bands. Experiments were performed on HUVEC 188 
cells either at basal level or activated with TNFα (10 ng/ml) as specifically indicated. 189 
 190 
2.6 Flow cytometry for cytokine detection 191 
The effects of ALCAR in modulating selected surface antigens (VEGFR2, CXCR4, 192 
PECAM-1) and cytokine release (VEGF, CCL2, CXCL12, Angiopoietin-1) was investigated by 193 
flow cytometry. HUVE cells where treated with ALCAR (1 or 10 mM) for 24 hrs. Following 194 
treatment, cells (3x105 per FACS tube) were detached and stained for surface antigens with the 195 
following PE conjugated mabs: anti-human VEGFR2/KDR (Clone #89106, R&D Systems) or 196 
CD184/CXCR4 (Clone #12G5, BD Pharmingen) for 30 minutes at 4°C. For cytokine detection, pre-197 
surface antigen stained cells were fixed and permeabilized using the CytoFix/Cytoperm kit (BD), 198 
accordingly to manufacturer, and stained with the following PE-conjugated Mabs: anti-human 199 
VEGF (Clone #23410, R&D Systems), CXCL12 (Clone #79018, R&D Systems); CCL2 (Clone 200 
#REA248, Miltenyi Biotec). For Angiopoietin-1 detecion, following primary antibodies incubation 201 
and washing, the anti-rabbit PE- conjugated secondary antibody (R&D Systems) was added. 202 
Fluorescence intensity for surface antigens and intracellular cytokines was detected by flow 203 
cytometry, on viable (SSC Vs FSC) gated cells, using a FACS Canto II analyzer. Experiments were 204 
performed on HUVEC cells either at basal level or activ ted with TNFα, as indicated. 205 
 206 
2.7 In vivo matrigel sponge assay, 207 
The ability of ALCAR to inhibit angiogenesis n vivo was investigated using the matrigel 208 
sponge assay. Unpolymerized liquid matrigel (10 mg/mL, Corning) was mixed with a cocktail of 209 
inflammatory pro-angiogenic factors that includes 100 ng/ml VEGF-A (PeproTech,), 2ng/ml TNFα 210 
(PeproTech) and 25 U/ml heparin (Sigma Aldrich), eith r alone or in combination with 1 or 10 mM 211 
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ALCAR. The mixture was brought to a final volume of 0.6 ml and injected subcutaneously into the 212 
flanks of 6- to 8-week-old C57/BL6 male mice [Charles River Laboratories, Calco (Lecco), Italy]. 213 
Two days before matrigel injection, mice received 1 or 10 mM ALCAR that was intraperitoneally 214 
(ip) injected in PBS to a total volume of 200 mL. The ALCAR administration was repeated the day 215 
of matrigel injection and after two days. All animals were housed in a conventional animal facility 216 
with 12 h light/dark cycles and fed ad libitum. In vivo experiments were performed in accordance 217 
with the Italian and European Community guidelines (D.L. 2711/92 No.116; 86/ 609/EEC 218 
Directive), the 3Rs declaration and within an approved protocol by the institutional ethics 219 
committee. Groups of 6 mice were used for each treatm nt. Four days after injection, the gels were 220 
recovered, minced digested with 1mg/mL CollagenaseII (Sigma Aldrich) for 30 minutes at 37°C, 221 
5% CO2. The cell suspension obtained was analyzed by multicolor flow cytometry for the detection 222 
of endothelial cells and macrophages.  223 
 224 
2.8 Flow cytometry for endothelial cells and macrophage detection in vivo 225 
The cell suspension obtained from the excised matrigel plugs was used to determine the 226 
infiltration of endothelial cells and macrophages. 3x105 cells per tube were stained for 30 minutes at 227 
4°C with the following anti-mouse monoclonal antibodies: PerCP-conjugated CD45, V500- 228 
conjugated CD3, FITC-conjugated CD31, APC-conjugated F4/80, all purchased from Immunotools 229 
(Friesoythe Germany). For FACS analysis, viable cells were gated according to physical parameters 230 
(FSC/SSC). Endothelial cells were identified as CD31+CD45-CD3-F4/80- cells and macrophages as 231 
CD45+CD3-CD31-F4/80+ cells 232 
 233 
2.9 Statistical analysis 234 
The statistical significance between multiple data sets was determined by one-way ANOVA, 235 
differences in cell growth curves were determined by two-way ANOVA using Graph-Pad PRISM. 236 
FACS data were analyzed by FACSDiva Software 6.1.2. Data are expressed as means ± SEM. 237 
 238 
3. RESULTS 239 
 240 
3.1 ALCAR inhibits capillary-like tube formation in vitro 241 
First, we investigated the effects of ALCAR on HUVEC proliferation by crystal violet 242 
(Supplemental Figure 1A) and MTT assay (Supplemental Figure 2A) showing that ALCAR acts on 243 
HUVEC proliferation in a dose-dependent manner. We also examined the impact of ALCAR on 244 
cell survival and growth inhibition of other human cell lines such as MRC-5 and peripheral blood 245 
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mononuclear cells (PBMCs) from healthy volunteers (Supplemental Figure 1A-C). We found that 246 
ALCAR exhibited little impact on the proliferation of normal cells at the highest concentration (10 247 
mM), while showed a significantly higher effect on the proliferation of endothelial cells 248 
(Supplemental Figure 1A-C). ALCAR might exert activities on angiogenesis by selectively 249 
targeting endothelial cells. Based on data obtained from cell proliferation assay, detection of 250 
apoptosis and cell cycle arrest (Supplemental Figure 2A-C), we selected two ALCAR 251 
concentrations, 1 and 10 mM. The selected concentrations are consistent with other preclinical 252 
studies [52, 60] and in line with several clinical trials. We assessed the effects of ALCAR on 253 
endothelial cell morphogenesis induced by FGF2 and VEGF by determining the ability of HUVECs 254 
to organize into capillary-like networks. We observed that ALCAR significantly inhibited the 255 
network like formation induced by VEGF/FGF2 in HUVE cells cultured on a matrigel layer (Figure 256 
1), as determined by the quantification of number and total length of master segments and number 257 
and total meshes area (P=0.0002). These results indicated that ALCAR inhibits HUVE 258 
morphogenesis in vitro. 259 
 260 
3.2 ALCAR reduces oxidative stress in hypoxic conditions 261 
ALCAR and others carnitine acyl esters effectively protect from oxidative damage [84] by 262 
acetyling membrane proteins [58], removing long-chain acyl CoAs from cell membranes [16] and 263 
by scavenging free radicals [34]. We tested the potential role of ALCAR on attenuating 264 
mitochondria-derived ROS generation in hypoxic conditions after 72 hours. We found that ALCAR 265 
reduced significantly the production of superoxides in the mitochondria of HUVE cells 266 
(Supplemental Figure 3) under a partial reduction in oxygen (1%), that could be involved in its 267 
protective role in preventing inflammation and endothelial dysfunction. 268 
 269 
3.3 ALCAR blocks HUVEC migration and invasion 270 
Adhesion to the extracellular matrix, migration and invasion are key steps in the 271 
angiogenesis and tumor- induced neovascularization. We therefore assessed the effects of ALCAR 272 
on these processes on HUVE cells in vitro. ALCAR significantly decreased (P<0.0001) HUVE cell 273 
adhesion on a fibronectin layer (Figure 2A) in a dose dependent manner. Accordingly, ALCAR at 274 
10 mM significantly interfered with HUVEC migration (P=0.0201) on collagen IV (Figure 2B) and 275 
invasion (P<0.0001) through a matrix layer, upon FBS as chemoattractant, according to published 276 
methods [2, 5] (Figure 2C), again in a dose dependent manner. Since we observed that ALCAR 277 
functionally inhibits HUVE cell adhesion, migration and invasion, we then investigated which 278 
molecular pathways involved in cell motility metastsis and invasion were targeted by ALCAR. We 279 
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observed significant down regulation of PECAM-1, FAK transcript levels and trends in down-280 
regulation of P-selectin (Supplemental Figure S3). CXCR4 and its ligand, CXCL12, known as key 281 
regulators in pro-angiogenic migratory phenotype [42, 50], were significantly downregulated by 282 
ALCAR at mRNA (P<0.0001; Figure 2D) and protein levels (P=0.031 and P=0.0010; Figure 2D-283 
E). CCL2, that acts on mononuclear cells and indirectly acts on endothelial cells to sustain 284 
inflammatory angiogenesis [38], was also inhibited by ALCAR (P<0.0001) (Figure 2E). 285 
 286 
3.4 ALCAR suppresses VEGF and VEGFR2 synthesis in endothelial cells 287 
VEGF/VEGFR2 interaction acts as a major regulator of angiogenesis [14, 29]. We 288 
investigated whether anti-angiogenic activities of ALCAR may target this axis both at gene 289 
expression and protein levels. Quantitative RT-PCR indicated that ALCAR treatment reduced, in a 290 
dose-dependent manner VEGFR2 and VEGF mRNA in endothelial cells (Figure 3A). This was 291 
confirmed by flow cytometry analysis (Figure 3B) and by western blot (Figure 3C). 292 
 The endothelial VEGF/VEGFR2 signaling network represents the key regulator of 293 
angiogenesis leading to endothelial cell proliferation, migration, survival and new vessel formation. 294 
We then moved to the specific protein levels and downstream signaling pathways involved. Focal 295 
Adhesion Molecule (FAK), which plays a crucial role in cell proliferation, survival and 296 
mobilization was found to be inhibited by ALCAR both at transcriptional (supplemental Figure S3) 297 
and protein phosphorylation level (pTyr397-FAK) (Figure 3D). The downstream pathways and 298 
VEGFR2 signaling intermediates pTyr416-Src, p-38 MAPK and p-Ser1248-PLCγ1 were also 299 
inhibited by ALCAR at 1 and 10mM (Figure 3D). Taken together, our results indicated that 300 
ALCAR targets multiple angiogenesis-related pathways nd exerts a direct effect on VEGF and 301 
VEGR2 signaling. 302 
 303 
3.5 ALCAR inhibits hypoxia induced endothelial cell morphogenesis and VEGF 304 
Oxygen availability causes different molecular switches which regulate synthesis and 305 
secretion of growth factors and inflammatory mediators within the tissue microenvironment. 306 
Hypoxia inducible factor (HIF-1α), the central mediator of hypoxic response, regulates several 307 
angiogenesis-related genes and VEGF is one of the primary target genes [65, 78]. Since hypoxia is 308 
present in tumors and is a major controller of the VEGF/VEGFR pathway, we evaluated the effect 309 
of ALCAR on the formation of capillary-like structures and VEGF expression in the hypoxic 310 
environment. Hypoxia induced significantly enhanced n twork formation in both SFM and under 311 
the stimulus of VEGF/FGF2 (P<0.01). ALCAR substantilly inhibited hypoxia-induced ability of 312 
HUVE cells to resemble capillary-like structures ona matrigel matrix as determined by the 313 
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quantification of number and total length of master s gments, number and total area of meshes 314 
(P<0.0001) (Figure 4A). This was accompanied by a downregulation of VEGF protein level, 315 
reflecting the HIF-1α trend, while VEGFR2 regulation seems not to be dependent on hypoxia 316 
(Figure 4), but was downregulated by ALCAR.  317 
 318 
3.6 ALCAR inhibits the activation of the NF-κB signaling pathway by TNFα 319 
Inflammation and angiogenesis are closely related events contributing to tumor insurgence 320 
and progression and NF-κB activation is considered a master inflammatory-regulator of 321 
angiogenesis [36]. Activation of NF-κB requires the degradation of inhibitor kappa B (IκB-α) that 322 
in turn forms a cytoplasmic and inactive complex with the p65-p50 heterodimer and is able to block 323 
the nuclear localization of the NF-κB subunits. We explored the effect of ALCAR pre-trea ment on 324 
NF-κB signaling on endothelial cells activated with TNFα, using functional angiogenesis assays, 325 
immunofluorescence and western blotting. Endothelial cells exposed to a cocktail of TNFα, VEGF 326 
and FGF2 (100 ng/ml) induced the formation of capill ry-like structures on matrigel which was 327 
significantly elevated over that of VEGF/FGF2 alone (P<0.05) and was abrogated by ALCAR 328 
treatment in a dose-dependent manner (Figure 5). Treatment with ALCAR also blocked the 329 
translocation of NF-κB p65 into nucleus after the addition of TNFα (Figure 6A) and inhibited the 330 
phosphorylation of NF-κB (Figure 6B). This was associated with decreased VEGFR2, FAK, 331 
PECAM-1, P-selectin and ICAM-1 at the transcription level, in a dose dependent manner (Figure 332 
7A). Data from the modulated transcripts were confirmed at the protein level by flow cytometry 333 
(Figure 7B) and western blot (Figure 7C). We found that pre-treatment with ALCAR followed by 334 
TNFα exposure downregulates the expression of VEGF, VEGFR2 and CXCR4, which are critical 335 
for endothelial cell survival, migration and invasion.  336 
 We also investigated whether ALCAR may impact on angiogenesis acting on the 337 
inflammatory stimuli by modulating leucocyte recruitment, we mimicked macrophage adhesion 338 
(human monocytic THP-1 cells) on an inflammatory (TNFα) activated endothelial layer. We found 339 
that pre-treatment of HUVE cells with 10 mM ALCAR resulted in significantly (P=0.0013) 340 
lowered number of adhered THP-1 cells on the endothelial cell layer (Figure 8). 341 
 342 
3.7 ALCAR inhibits inflammatory angiogenesis in vivo 343 
We investigated whether ALCAR was effective in inhibiting angiogenesis and inflammatory 344 
angiogenesis in vivo. Using the matrigel sponge assay, that allows to mimic a local inflammatory 345 
pro-angiogenic microenvironment in a matrix plug, we found that treatment with ALCAR at 1 and 346 
10 mM (corresponding to a dosage of 2 and 20 mg/Kg, respectively) significantly reduced 347 
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endothelial (CD31+ cells) content (Figure 9A). In addition, F4/80 FACS analysis showed a 348 
decreased population of macrophages were recruited into the matrigel plugs upon treatment (Figure 349 
9B-C). These results demonstrated that ALCAR was able to limit VEGF and TNFα (VTH)-induced 350 
endothelial cell and macrophage recruitments, confirming the results observed in vitro. 351 
 352 
4. DISCUSSION 353 
Angiogenesis and inflammation are necessary and complementary processes to support 354 
tumor insurgence and progression [4, 6]. With this knowledge, several anti-angiogenic agents have 355 
been developed and employed in the clinic to be combined with standard chemotherapy. There is a 356 
growing interest in identifying novel active compounds from natural sources [1, 4, 6, 10] in relation 357 
to their biological properties and potential health benefits. These compounds have been investigated 358 
based on their anti-proliferative, anti-oxidant and anti-angiogenic properties, and their ability to 359 
target both malignant transformed cells and the surrounding microenvironment [1, 4, 6, 10]. Based 360 
on this knowledge, many efforts have been addressed in the identification of diverse agents that 361 
target angiogenesis in a preventive approach (angioprevention) and interception [6],  for 362 
repurposing  (such as metformin, aspirin) or using phytochemicals [6],  363 
Carnitine, a micronutrient derived from an amino acid, is found in almost all cells of the 364 
body, and is involved in energy metabolism [33],  transport of long-chain fatty acids across the365 
membranes of mitochondria in muscle cells, and β-oxidation and the transport of fatty acids out of 366 
the mitochondria [33]. Carnitine supplementation has been largely reported to be beneficial in 367 
patients with primary and secondary carnitine defici n ies, mostly including chronic inflammatory 368 
diseases, such as diabetes, cardiovascular disorder and cancer [32]. Anti-inflammatory, antioxidant 369 
and free radical scavenging properties of ALCAR, as well as its stabilizing effects on mitochondrial 370 
membrane, have been reported [9, 15, 30, 57, 71]. 371 
Using novel highly sensitive mass spectrometry approach, based on Surface-Activated 372 
Chemical Ionization (SACI) with an Electrospray Ionization (ESI) source and bioinformatics 373 
analyses (SANIST platform) for prostate cancer (PCa) biomarker discovery, we found that 3 374 
molecules from the carnitine family (decanoyl-L-Carnitine, octanoyl-L-carnitine and 5-cis-375 
tetradecenoyl carnitine) were significantly decreased in serum sample from PCa patients as 376 
compared to those from individuals with BPH [3]. This finding suggests a potential protective role 377 
of carnitine against progression to PCa and we investigated whether these properties may act on 378 
angiogenesis and inflammation, two relevant hallmarks of cancer. Most of the studies on the effects 379 
of carnitine on cancer and angiogenesis are focused on carnitine transporters (CPT1 and CPT2) [45, 380 
70, 79], rather than on carnitine itself. 381 
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Here, we demonstrated for the first time that ALCAR acts as an anti-angiogenic and 382 
angiopreventive agent in two relevant microenvironme t settings; hypoxia and inflammation. We 383 
also unveil the molecular mechanisms involved. We first identified a dose range of ALCAR to be 384 
potentially employed in anti-angiogenesis and angiopreventive settings. Carnitine supplements 385 
present in the market cover the dosage of 2 g/day; we found that administration of ALCAR at 1 and 386 
10 mM, corresponding to 2 and 20 mg/Kg respectively, was sufficient able to reduce HUVEC cell 387 
proliferation without having toxicity. ALCAR selected concentrations showed no effects on  other 388 
normal cells proliferation, such as fibroblasts and peripheral blood mononuclear cells from heathy 389 
volunteers  390 
We investigated the ability of ALCAR to limit key functional steps of angiogenesis 391 
induction, such as endothelial cell adhesion, migration, invasion and formation of capillary like 392 
structures. We found that ALCAR was able to inhibit these key processes in HUVE cells. ALCAR 393 
is able to maintain the transition of mitochondrial membrane potential and suppress the induction of 394 
reactive oxygen species (ROS). It is recognized that ROS acts as signaling molecule in endothelial 395 
cells and can support angiogenesis through VEGF expression or VEGF receptors, mainly VEGFR2 396 
(Flk-1/KDR), and angiopoietin-I/Tie-2 receptors [23]. VEGF-VEGFRs signals constitute the most 397 
important signaling pathways in tumor angiogenesis [7, 72]. Among VEGFRs, VEGFR2 is the 398 
major receptor, which mediates the angiogenic activity of VEGF via different signaling pathways 399 
including MAPK family and Src-FAK complex. Molecular y, we found the functional alteration 400 
observed in HUVEC exposed to ALCAR was associated to ALCAR ability to target the VEGF-401 
VEGFR2 axis, whose reduction was observed both at transcript and protein levels. 402 
To better mimic the scenario occurring in the tumor microenvironment during tumor 403 
angiogenesis [12], we also treated HUVE cells with ALCAR in hypoxic and pro-inflammatory 404 
conditions, where we found ALCAR effective in limiting endothelial tube formation. ALCAR acted 405 
on VEGF and VEGFR2 downstream signaling pathways, including MAPK family and the activated 406 
complex Src-FAK that mediate endothelial cell migration and survival [17, 37, 51, 63]. We showed 407 
that the downregulation of SRC/FAK and MAPK family members by ALCAR was correlated with 408 
a functionally reduced endothelial cell adhesion, migration and invasion in a dose dependent 409 
manner.  410 
 In the presence of pathological angiogenesis, at the sprouting tips of growing vessels, the 411 
CXCL12/CXCR4 axis and CCL2 play a fundamental role in endothelial cell invasion, 412 
mobilization/migration, extravasation, directional migration, homing, and cell survival [40, 44, 53]. 413 
We demonstrated that ALCAR, in an inflammatory microenvironment, inhibits protein expression 414 
levels of CCL2, CXCL12 and CXCR4. Additionally, transcripts levels of cell-associated surface 415 
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proteins, such as PECAM-1 that are important drivers of cell migration [61, 83], were also 416 
significantly reduced. The inhibition of CXCR4 is particularly relevant, because of its expression is 417 
frequently upregulated and involvement in human cancer metastasis [11].  418 
Targeting mediators and cellular effectors of inflammation and angiogenesis could lead to 419 
improved prevention and treatment of tumors. Inflammation has been recognized as a relevant 420 
hallmark of cancer and is related to angiogenesis [36]. During the angiogenic switch this 421 
interaction becomes more relevant, since inflammatory cells recruited into the tissues can also 422 
support angiogenesis by acquiring altered phenotypes and release pro-angiogenic factors [19, 423 
20]. 424 
The principal source of ROS, mitochondria, regulate innate immunity responses via two 425 
major pathways including either direct activation of inflammasome complexes or upregulation of 426 
redox-sensitive transcription factors such as NF-ĸB [31]. Expression of genes encoding 427 
inflammatory cytokines, adhesion molecules, enzymes and angiogenic factors are regulated by NF-428 
κB activation [43, 59]. We showed that pre-treatment of HUVEC with ALCAR reduced TNFα 429 
mediated angiogenesis by decreasing p-NF-κB translocation into the nucleus, consequently 430 
blocking the upregulation of chemokines and adhesion molecules involved in inflammatory 431 
response [27].  432 
Macrophages are among the most abundant immune infiltrate in inflamed tissues and induce 433 
a pro-angiogenic environment [48, 49]. In microenvironment of smoldering inflammation, NF-κB 434 
plays a crucial role in the macrophage infiltration, also interconnected with angiogenesis that 435 
predisposes individuals towards developing cancer mtastasis [35]. Targeting NF-κB by ALCAR 436 
effectively blocked both endothelial and macrophage recruitment in vivo and lowered the 437 
expression of ICAM-1, supporting the hypothesis that ALCAR may directly and indirectly (by 438 
inhibiting inflammation) inhibit angiogenesis. 439 
Given the dietary antioxidants properties on preventing tumor angiogenesis by acting on oxidative 440 
stress-induced pathological angiogenesis we speculat  th t ALCAR inhibits inflammatory-induced 441 
angiogenesis possibly due to its antioxidant ability and stabilizing effects on mitochondria [8]. Our 442 
results highlight the anti-angiogenic and anti-inflammatory properties of ALCAR and allow the 443 
identification of major molecular pathways through w ich ALCAR inhibits angiogenesis. Beside 444 
the anti-angiogenic agents that have been clinically approved by the US FDA, our data showed that 445 
ALCAR downregulates angiogenesis by multiple and overlapping mechanisms of action. To our 446 
knowledge this is the first study demonstrating that ALCAR is anti-angiogenic, suggesting a 447 
potential employment of ALCAR as a possible dietary supplement in the prevention of tumor and 448 
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inflammatory angiogenesis to be used as chemo/angioprevention approaches in subjects at high risk 449 
to develop cancer. 450 
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Figure 1: Effects of ALCAR on capillary-like structure formation of HUVE cells. HUVE cells 
were pretreated with ALCAR at 1 and 10mM for 24 hours or treated with vehicle alone, were then 
placed in 96-well plates coated with a layer of Matrigel (15 × 103 per well). SFM: cells cultured in 
serum-free EGM-2 medium as a negative control; NT: cells treated with vehicle alone in EGM-2 
medium supplemented with VEGF+FGF2. Six hours after plating on matrigel, tubular structures 
were photographed at 5X magnification and quantified by the Angiogenesis analyzer ImageJ tool 
kit. Pre-treatment with ALCAR at 1 and 10mM for 24 hours inhibited HUVEC ability to form 
capillary-like structures on matrigel compared to vehicle treated cells (NT). Data are showed as 
Mean ± SEM. *p<0.05; **p<0.01; ***p<0.0001 versus VEGF +FGF2 alone or as indicated by the 
bars. 
 
Figure 2: Effects of ALCAR on chemotactic motility of HUVE cells. 
ALCAR at 1 and 10 mM concentrations can interfere with crucial steps of angiogenesis by 
decreasing HUVEC (A) adhesion, (B) migration and (C) invasion, as compared to vehicle treated 
cells (NT); FBS- cells in serum-free EGM-2 medium as a negative control; FBS+ cells in medium 
containing 10% FBS as a positive control. All experim nts were performed three times in duplicate. 
(D) qPCR and FACS analysis showed an inhibition of CXCR4 transcript and protein levels in 
HUVECs treated with ALCAR at 1 and 10mM. The gene expr ssion of CXCR4 is quantified 
relatively to NT cells, normalized to the housekeeping gene, GAPDH (n= 3 independent 
experiments). (E) FACS analysis for CXCL12 and CCL2 confirmed the downregulation of markers 
involved in cell motility metastasis and invasion (n= 4-5 independent experiments). Results are 
expressed as percentage of positive cells over NT and showed as Mean ± SEM *p<0.05; **p<0.01; 
***p<0.0001 as indicated by the bars (One-Way ANOVA). 
 
Figure 3: Effects of ALCAR on VEGF and VEGFR2 synthesis of HUVE cells.  
(A) qPCR analysis demonstrates an inhibition of VEGF/VEGFR2 transcripts in HUVECs treated 
with ALCAR 1 and 10mM after 24h. mRNA levels [2^ (-delta delta Ct)] were calculated relatively 
to NT cells, normalized to the housekeeping gene, GAPDH (n= 4 independent experiments). (B-C) 
FACS analysis for VEGF/VEGFR2 confirmed the inhibition at protein level (n= 4-5 independent 
experiments). Further validation was obtained by western blot analysis, the graphs show 
quantification of VEGF and VEGFR2 (n= 4 independent experiments). (D) ALCAR inhibited the 
activation of VEGFR2 downstream cascade: pTyr397-FAK, pTyr416-Src, p-38 MAPK, p-Ser1248-
PLCγ.  
 
Figure 4: Effect of ALCAR on the hypoxia-induced angiogenesis 
(A) Activation of HUVE cells in hypoxic conditions for 72 h, followed by treatment with ALCAR 1 
and 10 mM for 24h resulted in significantly reduced ability to form capillary-like structures on 
matrigel compared to vehicle treated HUVE cells. Microphotographs were taken at 5X 
magnification, representative images are shown. Images were quantified by Angiogenesis analyzer 
ImageJ tool kit. Data are showed as Mean ± SEM. *p<0.05; **p<0.01; ***p<0.0001 vs cells in 
normoxic conditions or as indicated by the bars. (B) WB showing that ALCAR reduces hypoxia-
induced angiogenesis by downregulating VEGF and VEGFR2 following treatment with ALCAR 
(n= 3 independent experiments).  
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Figure 5: Effect of ALCAR on TNFα-induced capillary-like structure formation 
Pre-treatment with ALCAR at 1 and 10 mM concentrations, of HUVE cells stimulated with 10 
ng/ml of TNFα (10 ng/ml) for 6h resulted in significantly reduced ability to form capillary-like 
structures on matrigel. Microphotographs were taken at 5X magnification, representative images are 
shown. Images were quantified by Angiogenesis analyzer ImageJ tool kit. Data are showed as Mean 
± SEM. *p<0.05; **p<0.01; ***p<0.0001 vs VEGF+FGF2+TNFα as indicated by the bars. 
 
Figure 6: ALCAR inhibits the TNFα-induced p65 phosphorylation and nuclear translocation 
(A) HUVE cells were incubated with ALCAR 1 and 10mM for 6h and followed by TNFα (10 
ng/ml) stimulation for 30 min. After fixation, cells were stained with specific anti-NFκB-p65 
(Ser536) antibody followed by secondary antibody Alexa Flour 488 (green). Actin filaments were 
stained with rhodamine phalloidin, while nucleus was counterstained with DAPI (blue) and 
captured with a 20X magnification objective (Axio Observer A1, Zeiss, Germany). Scale bars: 50 
µm. Images were acquired for each fluorescence channel and were merged using AxioVision 
Software. (B) Representative western blot images showed a significantly reduced phosphorylation 
of anti-NFκB-p65 (Ser536) in HUVE cells incubated with ALCAR 1 and 10 mM for 6h, followed 
by TNFα (10 ng/ml) stimulation for 30 min. The graphs show quantification of anti-NFκB-p65 
(Ser536) indicating significantly differences (P< 0.0001) of ALCAR treated vs non-treated cells. 
Data are expressed as Mean ± SEM (n= 5 independent experiments). 
 
Figure 7: ALCAR inhibits TNFα induced proangiogenic and NFκB-regulated pathways. 
(A) qPCR analysis showing an inhibition of VEGFR2, FAK, P-Selectin, PECAM-1, ICAM-1 
VCAM-1 transcript in HUVE cells incubated with ALCAR (1 and 10 mM) for 24h and followed by 
TNFα (10 ng/ml) stimulation for 30 min as compared to non-treated cells. mRNA levels [2^ (-delta 
delta Ct)] were calculated relatively to TNFα-stimulated HUVE cells, normalized to the 
housekeeping gene, GAPDH (n= 4 independent experiments). (B) FACS analysis showing a 
downregulation of angiogenic markers (VEGF, VEGFR2 and ANGIOP-1) and invasion markers 
(CXCR4), expressed as percentage of positive cells over TNFα-stimulated cells (n= 4-7 
independent experiments). (C) Further validation obtained by WB analysis confirmed the inhibition 
at protein level of VEGF, VEGFR2 and ICAM-1, the graphs show quantification of VEGF, 
VEGFR2, ICAM-1, VCAM-1 (n= 4 independent experiments). Results are showed as Me n ± SEM 
*p<0.05; **p<0.01; ***p<0.0001 vs TNFα-treated cells or as indicated by the bars (One-Way 
ANOVA). 
 
Figure 8: Effects of ALCAR on the adhesion of monocytes to HUVE cells  
THP-1 monocytic cell adhesion to HUVEC is reduced by ALCAR (1 and 10 mM). After treatment 
of a monolayer HUVE cells with ALCAR and activation with TNFα (10 ng/ml), calcein AM-
labelled THP-1 cells were added on a top of HUVEC monolayer and incubated for 3h. After 
washing to remove non-adherent monocytes, calcein-AM-labelled THP-1 cells (green) adhering to 
HUVECs were counted. Results are showed as Mean ± SEM *p<0.05; **p<0.01; ***p<0.0001 vs 
TNFα- activated cells as indicated by the bars (One-Way ANOVA). 
 
Figure 9: ALCAR inhibits angiogenesis in vivo 
Flow cytometry analysis for endothelial cells and macrophage infiltration in the excised 
Matrigel plugs revealed ALCAR ability to inhibit VTH-induced A) CD31+ endothelial cell 
infiltration and B) CD45+F4/80+ macrophage infiltration into the matrigel plugs. C) Representative 
Downloaded for Anonymous User (n/a) at SBBL Sistema Bibliotecario Biomedico Lombardo from ClinicalKey.com by Elsevier on May 09, 2018.













dot plots for macrophages infiltration in matrigel plugs, as determined by flow cytometry. Results 
are showed as Mean ± SEM *p<0.05; **p<0.01 vs controls, One-Way ANOVA. 
 
Figure 10: Schematic presentation of the anti-angiogenic signalling pathways regulated by 
ALCAR in HUVE cells 
Proposed mechanism for the inhibition of angiogenesis by ALCAR: i) via inhibition of 
VEGF/VEGFR2-mediated signalling pathways; ii) via downregulation of HIF-1α and VEGF and 
iii) by blocking the activation of NF-κB, and downregulation of ICAM. Arrows indicate regulations 
by ALCAR treatment observed in our experiments.  
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• ALCAR targets VEGF/VEGFR2 axis and its downstream signaling intermediates. 
• ALCAR blocks endothelial cell migration/invasion acting on CXCR4/ CXCL12 and CCL2. 
• ALCAR downregulates inflammatory induced angiogenesis by inhibiting NF-κB and 
ICAM-1. 
• ALCAR decrease endothelial cells and macrophage recruitment in vivo. 
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